Successful treatment with nab-paclitaxel and gemcitabine after FOLFIRINOX failure in a patient with metastasized pancreatic adenocarcinoma

Onkologie(Czech Republic)

Volumn 36, Issue 12, 2013, Pages 763-765

  Berger, Anne K ^a   Weber, Tim F ^a   Jäger, Dirk ^a   Springfeld, Christoph ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Chemotherapy: palliative, second line; Pancreatic cancer

Indexed keywords

ANTICOAGULANT AGENT; CA 19-9 ANTIGEN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER SIZE; CASE REPORT; CLINICAL PROTOCOL; COMMON COLD; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPNEA; ECHOGRAPHY; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; LUNG EMBOLISM; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; PANCREAS ADENOCARCINOMA; PANCREAS BIOPSY; PATIENT CARE; POLYNEUROPATHY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VEIN THROMBOSIS;

ADENOCARCINOMA; ALBUMINS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; PANCREATIC NEOPLASMS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84892393346     PISSN: 0378584X     EISSN: 14230240     Source Type: Journal    
DOI: 10.1159/000356811     Document Type: Article

References (15)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Hidalgo M: Pancreatic cancer. N Engl J Med 2010; 362:1605-1607.
3. Vincent A, Herman J, Schulick R, et al.: Pancreatic cancer. Lancet 2011;378:607-620.
4. Werner J, Combs SE, Springfeld C, et al.: Advanced-stage pancreatic cancer: Therapy options. Nat Rev Clin Oncol 2013;10:323-333.
5. Burris HA 3rd, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413.
6. Conroy T, Desseigne F, Ychou M, et al.: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-1825.
7. Von Hoff DD: Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). Gastrointestinal Cancers Symposium, 2013, abstract. J Clin Oncol 2012;30 Suppl. 34:LBA148.
8. Pelzer U, Schwaner I, Stieler J, et al.: Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III study from the German CONKO-study group. Eur J Cancer 2011;47:1676-1681.
9. Oken MM, Creech RH, Tormey DC, et al.: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;15:649-655.
10. Eisenhauer EA, Therasse P, Bogaerts J, et al.: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
11. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0, published: 28 May 2009 (v4.03: 14 June 2010) U.S. Department of Health and Human Services, National Institutes of Health, http://evs.nci.nih.gov/ftp1/CTCAE/ CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf
12. Iacobuzio-Donahue CA, Velculescu VE, Wolfgang CL, et al.: Genetic basis of pancreas cancer development and progression: Insights from whole-exome and whole-genome sequencing. Clin Cancer Res 2012;18:4257-4265.
13. Collisson EA, Sadanandam A, Olson P, et al.: Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 2011;17:500-503.
14. Maréchal R, Bachet JB, Mackey JR, et al.: Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 2012;143:664-674 e1-6.
15. Cui Y, Brosnan JA, Blackford AL, et al.: Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity. Clin Cancer Res 2012;18:6519-6530.